QUOTED. Aug. 20, 2018. Bradley Thompson.
Attorney and industry advocate Bradley Merrill Thompson argues in a recent Medtech Insight article that US FDA is pursuing expanded authorities for collecting and acting on post-market device data without congressional authorization. Read one of Thompson's recommendations here.
Click here for a free trial of Medtech Insight